| Apixaban versus warfarin in patients with atrial fibrillation CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ... New England Journal of Medicine 365 (11), 981-992, 2011 | 10331 | 2011 |
| Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic … MH Forouzanfar, A Afshin, LT Alexander, HR Anderson, ZA Bhutta, ... The lancet 388 (10053), 1659-1724, 2016 | 7390 | 2016 |
| Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic … T Vos, RM Barber, B Bell, A Bertozzi-Villa, S Biryukov, I Bolliger, ... The lancet 386 (9995), 743-800, 2015 | 6484 | 2015 |
| Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and … JD Stanaway, A Afshin, E Gakidou, SS Lim, D Abate, KH Abate, ... The Lancet 392 (10159), 1923-1994, 2018 | 5493* | 2018 |
| Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global … H Wang, M Naghavi, C Allen, RM Barber, ZA Bhutta, A Carter, DC Casey, ... The lancet 388 (10053), 1459-1544, 2016 | 4807 | 2016 |
| Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global … H Wang, M Naghavi, C Allen, RM Barber, ZA Bhutta, A Carter, DC Casey, ... The lancet 388 (10053), 1459-1544, 2016 | 4248 | 2016 |
| Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying … CJL Murray, RM Barber, KJ Foreman, AA Ozgoren, F Abd-Allah, SF Abera, ... The Lancet 386 (10009), 2145-2191, 2015 | 2207* | 2015 |
| Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990 … SI Hay, AA Abajobir, KH Abate, C Abbafati, KM Abbas, F Abd-Allah, ... The Lancet 390 (10100), 1260-1344, 2017 | 1568 | 2017 |
| Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 NJ Kassebaum, RM Barber, ZA Bhutta, L Dandona, PW Gething, SI Hay, ... The lancet 388 (10053), 1775-1812, 2016 | 1067 | 2016 |
| Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation RD Lopes, G Heizer, R Aronson, AN Vora, T Massaro, R Mehran, ... New England Journal of Medicine 380 (16), 1509-1524, 2019 | 986 | 2019 |
| Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial JD Easton, RD Lopes, MC Bahit, DM Wojdyla, CB Granger, L Wallentin, ... The Lancet Neurology 11 (6), 503-511, 2012 | 361 | 2012 |
| Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin … CM O'Connor, AB Miller, JEA Blair, MA Konstam, P Wedge, MC Bahit, ... American heart journal 159 (5), 841-849. e1, 2010 | 300 | 2010 |
| Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other … A Avezum, RD Lopes, PJ Schulte, F Lanas, BJ Gersh, M Hanna, P Pais, ... Circulation 132 (8), 624-632, 2015 | 282 | 2015 |
| Post-myocardial infarction heart failure MC Bahit, A Kochar, CB Granger JACC: Heart failure 6 (3), 179-186, 2018 | 276 | 2018 |
| Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised … RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell, MC Bahit, ... The Lancet 380 (9855), 1749-1758, 2012 | 261 | 2012 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 221 | 2019 |
| Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind … EM Ohman, MT Roe, PG Steg, SK James, TJ Povsic, J White, F Rockhold, ... The Lancet 389 (10081), 1799-1808, 2017 | 215 | 2017 |
| A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial D Vinereanu, RD Lopes, MC Bahit, D Xavier, J Jiang, HR Al-Khalidi, W He, ... The Lancet 390 (10104), 1737-1746, 2017 | 182 | 2017 |
| Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in … S Goto, J Zhu, L Liu, BH Oh, DM Wojdyla, P Aylward, MC Bahit, BJ Gersh, ... American heart journal 168 (3), 303-309, 2014 | 146 | 2014 |
| Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990 … GBD Collaborators, MH Forouzanfar, L Alexander, VF Bachman, ... The Lancet 386 (10010), 2287-2323, 2015 | 108 | 2015 |
